Emerging Markets Earnings Roundup: Astra Zeneca and Teva (Part 6)
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca reports 21% growth in China, representing $72 million of the $154 million sales increase in emerging markets; and Teva reports $1.47 billion loss due to at-risk launches.